• Profile
Close

Fibroscan liver stiffness after anti‐viral treatment for hepatitis C is independently associated with adverse outcomes

Alimentary Pharmacology and Therapeutics Sep 25, 2020

Vutien P, Kim NJ, Moon AM, et al. - As anti‐viral treatment for hepatitis C virus (HCV) infection results in reduction of fibroscan‐derived liver stiffness, researchers here examined if liver stiffness pre‐ or post‐anti‐viral therapy is linked with the development of decompensated cirrhosis, hepatocellular carcinoma (HCC) or death. They conducted a retrospective cohort study of US veterans who began HCV treatment and had at least one liver stiffness before (n = 492) or after (n = 877) HCV therapy. In the posttreatment liver stiffness cohort, decompensated cirrhosis developed in 21 patients (2.4%), HCC developed in 26 patients (3.0%) and death or liver transplantation was reported in 57 patients (6.5%) during a mean follow‐up of 27.3 months. Observations revealed independent correlation of posttreatment liver stiffness > 20 kPa, but not of pretreatment liver stiffness, with the development of decompensated cirrhosis and the composite outcome in multivariable analyses. They emphasize that liver stiffness should be measured after anti‐viral treatment as it prognosticates adverse outcomes even beyond routinely available clinical predictors.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay